CRISPR/Cas9 工程化成年小鼠肝脏证实 Dnajb1-Prkaca 基因融合足以诱导类似纤维板层型肝细胞癌的肿瘤
研究利用 CRISPR/Cas9 在水动力尾静脉注射的 8 周龄雌性 FVB/N 小鼠肝脏中构建 Dnajb1-Prkaca 基因融合,14 个月后 15 只实验小鼠中 12 只发生肿瘤,而 11 只对照小鼠均未发生;肿瘤具有人类纤维板层型肝细胞癌的组织学、细胞学、表达谱和基因组特征。
要点
- 15 只接受 Dnajb1-Prkaca 融合载体的小鼠中 12 只发生肿瘤,11 只对照小鼠均未发生。
- 小鼠肿瘤具备人类纤维板层型肝细胞癌的组织学与细胞学特征。
- 肿瘤表达谱改变与人类纤维板层型肝细胞癌相似,且缺乏常见肝癌相关基因突变。
核心结论
- 利用 CRISPR/Cas9 技术在野生型小鼠中生成 Dnajb1-Prkaca 融合基因足以启动形成具有人类纤维板层型肝细胞癌许多特征的肿瘤。
- 作者认为可开发阻断 DNAJB1-PRKACA 的策略作为该型肝癌的治疗方法。
研究设计与样本
- 研究将设计用于使 Dnajb1 外显子 1 与 Prkaca 外显子 2 并置、创建 FL-HCC 相关 Dnajb1-Prkaca 基因融合的 CRISPR/Cas9 载体,或对照 Cas9 载体,通过水动力尾静脉注射递送至 8 周龄雌性 FVB/N 小鼠肝脏。
- 这些小鼠无其他工程化遗传改变,未暴露于肝毒素或致癌物。
- 递送后 14 个月收集肝组织,用 PCR 检测 Dnajb1-Prkaca 融合,并用组织学、免疫组化、RNA 测序和全外显子测序进行表征。
主要发现
- 15 只接受诱导 Dnajb1-Prkaca 基因融合载体的小鼠中 12 只肝脏发生肿瘤,而 11 只接受对照载体的小鼠均未发生肿瘤。
- 肿瘤含有 Dnajb1-Prkaca 基因融合,并具有人类 FL-HCC 的组织学和细胞学特征:大的多边形细胞,胞质颗粒状、嗜酸性且富含线粒体,核仁明显,以及肝细胞和胆管细胞标志物。
- 比较小鼠肿瘤与非肿瘤肝细胞之间的基因表达水平,发现与人类 FL-HCC 中检测到的相似改变,包括影响细胞周期和有丝分裂调控的基因。
- 对 Dnajb1-Prkaca 融合诱导的小鼠肿瘤进行基因组分析,发现缺乏人类 FL-HCC 中所观察到的常见肝癌相关基因突变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a primary liver cancer that predominantly affects children and young adults with no underlying liver disease. A somatic, 400 Kb deletion on chromosome 19 that fuses part of the DnaJ heat shock protein family (Hsp40) member B1 gene (DNAJB1) to the protein kinase cAMP-activated catalytic subunit alpha gene (PRKACA) has been repeatedly identified in patients with FL-HCC. However, the DNAJB1-PRKACA gene fusion has not been shown to induce liver tumorigenesis. We used the CRISPR/Cas9 technique to delete in mice the syntenic region on chromosome 8 to create a Dnajb1-Prkaca fusion and monitored the mice for liver tumor development. METHODS: We delivered CRISPR/Cas9 vectors designed to juxtapose exon 1 of Dnajb1 with exon 2 of Prkaca to create the Dnajb1-Prkaca gene fusion associated with FL-HCC, or control Cas9 vector, via hydrodynamic tail vein injection to livers of 8-week-old female FVB/N mice. These mice did not have any other engineered genetic alterations and were not exposed to liver toxins or carcinogens. Liver tissues were collected 14 months after delivery; genomic DNA was analyzed by PCR to detect the Dnajb1-Prkaca fusion, and tissues were characterized by histology, immunohistochemistry, RNA sequencing, and whole-exome sequencing. RESULTS: Livers from 12 of the 15 mice given the vectors to induce the Dnajb1-Prkaca gene fusion, but none of the 11 mice given the control vector, developed neoplasms. The tumors contained the Dnajb1-Prkaca gene fusion and had histologic and cytologic features of human FL-HCCs: large polygonal cells with granular, eosinophilic, and mitochondria-rich cytoplasm, prominent nucleoli, and markers of hepatocytes and cholangiocytes. In comparing expression levels of genes between the mouse tumor and non-tumor liver cells, we identified changes similar to those detected in human FL-HCC, which included genes that affect cell cycle and mitosis regulation. Genomic analysis of mouse neoplasms induced by the Dnajb1-Prkaca fusion revealed a lack of mutations in genes commonly associated with liver cancers, as observed in human FL-HCC. CONCLUSIONS: Using CRISPR/Cas9 technology, we found generation of the Dnajb1-Prkaca fusion gene in wild-type mice to be sufficient to initiate formation of tumors that have many features of human FL-HCC. Strategies to block DNAJB1-PRKACA might be developed as therapeutics for this form of liver cancer.
引用
- Engelholm LH, Riaz A, Serra D, et al. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma. Gastroenterology. 2017. PMID: 28923495. doi:10.1053/j.gastro.2017.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。